5156 |
PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA |
PDGFRA |
CD140A |
PDGFR-2 |
PDGFR2 |
173490 |
8803 |
ENSG00000134853 |
OTTHUMG00000128699 |
RHEPDGFRA |
Platelet-derived growth factor receptor alpha |
Alpha platelet-derived growth factor receptor |
Platelet-derived growth factor receptor 2 |
Platelet-derived growth factor alpha receptor |
Alpha-type platelet-derived growth factor receptor |
PDGF-R-alpha |
PDGFR-alpha |
CD140a antigen |
CD140 antigen-like family member A |
CD_antigen=CD140a |
PGFRA_HUMAN |
P16234 |
ALPHA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (PDGF-R-ALPHA) (CD140A ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P16234] |
PDGFR |
GAS9 |
38 |
PA33147 |
T53524 |
Human Readable Name | DRUGGABLE GENOME |
Target Subclass | PDGFR |
Target Subclass | KInase |
Target Main Class | Receptors |
Transmembrane Helix Count | 1 |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
Uniprot Status | Swiss-Prot |
Interpro Acc | IPR001245 |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Type | Domain |
Human Readable Name | KINASE |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
EXTERNAL SIDE OF PLASMA MEMBRANE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
antibody (inhibitory) |
antagonist (inhibitory) |
Trial Name | IMC-3G3 |
Novel drug target | Established target |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Platelet-derived growth factor receptor agonist |
Direct Interaction | yes |
Trial Name | becaplermin,Regranex |
inhibitor (inhibitory) |
Clinical Status | preclinical |
Pathway | activation |
Variant Effect | gain-of-function |
antibody (inhibitory) |
Notes |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Clinical Status | preclinical |
Pathway | activation |
Variant Effect | gain-of-function |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
Approval Status | Preclinical - Cell culture |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | MP-470 |
Mechanism of Interaction | Platelet-derived growth factor receptor alpha inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
antibody (inhibitory) |
Notes |
inhibitor (inhibitory) |
Notes | |
Trial Name | BIBF-1120,Vargatef |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
Approval Status | Preclinical - Cell culture |
n/a |
Variant Effect | gain-of-function |
Pathway | activation |
Clinical Status | preclinical |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
Trial Name | vatalanib, PTK 787 |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | masitinib, AB1010 |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Trial Name | E7080 |
Novel drug target | Established target |
n/a |
Trial Name | telatinib |
Novel drug target | Established target |
n/a |
Novel drug target | Established target |
Trial Name | E-10030 |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Indication/Tumor Type | gastrointestinal stromal tumor |
inhibitor (inhibitory) |
Notes |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
n/a |
Trial Name | axitinib, AG-013736 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
inhibitor (inhibitory) |
Trial Name | ENMD-2076 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
PDGFRA | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
P16234 | Uniprot Accession |
5156 | Entrez Gene Id |
PDGFRA | Uniprot Gene Name |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
Uniprot Status | Swiss-Prot |
KINASE, DRUGGABLE GENOME |
PDGFRA | Gene Symbol |
ENSG00000134853 | Ensembl Gene Id |
PGFRA_HUMAN | Uniprot Id |
Target Subclass | PDGFR |
Target Subclass | KInase |
Target Main Class | Receptors |
ENSG00000134853 | Ensembl Gene Id |
PDGFRA | Display Id |
ALPHA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (PDGF-R-ALPHA) (CD140A ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P16234] | Description |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
PDGFRA | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
5156 | CKB Entrez Id |
PDGFRA | CKB Gene Synonym |
CD140A | CKB Gene Synonym |
5156 | Entrez Gene ID |
38 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
ENSG00000134853 | Gene Symbol |
PDGFRA | Ensembl Id |
DRUGGABLE GENOME |
5156 | Entrez Gene Id |
PDGFRA | MyCancerGenome Gene Symbol |
PDGFR-alpha | MyCancerGenome Reported Gene Name |
PDGFRA | Gene Symbol |
PDGF-R-alpha | UNIPROT |
RHEPDGFRA | GENE_SYMBOL |
PDGFRA | GENE_SYMBOL |
5156 | OncoKB Entrez Id |
PDGFR2 | OncoKB Gene Synonym |
RHEPDGFRA | OncoKB Gene Synonym |
PA33147 | PharmGKB ID |
PDGFR2 | GO Gene Synonym |
RHEPDGFRA | GO Gene Synonym |
EXTERNAL SIDE OF PLASMA MEMBRANE |
PDGFRA | Gene Symbol |
CLINICALLY ACTIONABLE |
5156 | Gene ID |
CD140A | dGene Synonym |
PDGFR-2 | dGene Synonym |
KINASE, TYROSINE KINASE |
PDGFRA | TTD Gene Abbreviation |
T53524 | TTD Target ID |
Platelet-derived growth factor receptor alpha | Gene Name |
P16234 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
DRUG RESISTANCE |